The interplay of immunotherapy and chemotherapy, a novel approach;L'immunothérapie au service de la chimiothérapie, de nouvelles avancées

Medecine/Sciences

Volumn 32, Issue 4, 2016, Pages 353-361

  Hanoteau, Aurélie ^a   Henin, Coralie ^a   Moser, Muriel ^a  

^a UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ANIMAL; DRUG EFFECTS; DRUG POTENTIATION; HUMAN; IMMUNOLOGY; IMMUNOSURVEILLANCE; IMMUNOTHERAPY; MULTIMODALITY CANCER THERAPY; NEOPLASMS; PATHOLOGY; PHYSIOLOGY; PROCEDURES; TREATMENT OUTCOME; TUMOR ESCAPE;

ANIMALS; ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; DRUG SYNERGISM; HUMANS; IMMUNOLOGIC SURVEILLANCE; IMMUNOTHERAPY; NEOPLASMS; TREATMENT OUTCOME; TUMOR ESCAPE;

EID: 84969590540     PISSN: 07670974     EISSN: 19585381     Source Type: Journal    
DOI: 10.1051/medsci/20163204013     Document Type: Article

References (54)

1. Krumbhaar EB, Krumbhaar HD. The blood and bone marrow in yelloe cross gas (mustard gas) poisoning. J Med Res 1919; 40: 497-508.
2. DeVita VT, Chu E. A history of cancer chemotherapy. Cancer Res 2008; 68: 8643-8653.
3. Zitvogel L, Apetoh L, Ghiringhelli F, et al. Immunological aspects of cancer chemotherapy. Nat Rev Immunol 2008; 8: 59-73.
4. Suzuki E, Sun J, Kapoor V, et al. Gemcitabine has significant immunomodulatory activity in murine tumor models independent of its cytotoxic effects. Cancer Biol Ther 2007; 6: 880-885.
5. Kroemer G, Galluzzi L, Kepp O, et al. Immunogenic cell death in cancer therapy. Annu Rev Immunol 2013; 31: 51-72.
6. Denkert C, Loibl S, Noske A, et al. Tumor-Associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol 2010; 28: 105-113.
7. Fridman WH, Galon J, Pages F, et al. Prognostic and predictive impact of intra-And peritumoral immune infiltrates. Cancer Res 2011; 71: 5601-5605.
8. Ma Y, Mattarollo SR, Adjemian S, et al. CCL2/CCR2-dependent recruitment of functional antigen-presenting cells into tumors upon chemotherapy. Cancer Res 2014; 74: 436-445.
9. Rahir G, Wathelet N, Hanoteau A, et al. Cyclophosphamide treatment induces rejection of established P815 mastocytoma by enhancing CD4 priming and intratumoral infiltration of P1E/H-2K(d)-specific CD8(+) T cells. Int J Cancer 2014; 134: 2841-2852.
10. Williams KM, Hakim FT, Gress RE. T cell immune reconstitution following lymphodepletion. Semin Immunol 2007; 19: 318-330.
11. + T cells in vivo. Cancer Immunol Immunother 2012; 61: 2343-2356.
12. Hong M, Puaux AL, Huang C, et al. Chemotherapy induces intratumoral expression of chemokines in cutaneous melanoma, favoring T-cell infiltration and tumor control. Cancer Res 2011; 71: 6997-7009.
13. Van Pel A, Boon T. Protection against a nonimmunogenic mouse leukemia by an immunogenic variant obtained by mutagenesis. Proc Natl Acad Sci USA 1982; 79: 4718-4722.
14. Grulich AE, van Leeuwen MT, Falster MO, et al. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-Analysis. Lancet 2007; 370: 59-67.
15. Shankaran V, Ikeda H, Bruce AT, et al. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 2001; 410: 1107-1111.
16. Koebel CM, Vermi W, Swann JB, et al. Adaptive immunity maintains occult cancer in an equilibrium state. Nature 2007; 450: 903-907.
17. Coulie PG, Van den Eynde BJ, van der Bruggen P, et al. Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy. Nat Rev Cancer 2014; 14: 135-146.
18. Igney FH, Krammer PH. Tumor counterattack: fact or fiction ? Cancer Immunol Immunother 2005; 54: 1127-1136.
19. Nishikawa H, Sakaguchi S. Regulatory T cells in cancer immunotherapy. Curr Opin Immunol 2014; 27: 1-7.
20. + suppressor T-cells. Cancer Res 1989; 49: 1649-1654.
21. Lutsiak MEC, Semnani RT, de Pascalis R, et al. Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. Blood 2005; 105: 2862-2868.
22. Walter S, Weinschenk T, Stenzl A, et al. Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. Nat Med 2012; 18: 1254-1261.
23. + regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol Immunother 2007; 56: 641-648.
24. + regulatory T cells by low-dose cyclophosphamide is explained by reduced intracellular ATP levels. Cancer Res 2010; 70: 4850-4858.
25. + T cell activation and cell death. Eur J Immunol 2005; 35: 3424-3432.
26. Zhang L, Dermawan K, Jin M, et al. Differential impairment of regulatory T cells rather than effector T cells by paclitaxel-based chemotherapy. Clin Immunol 2008; 129: 219-229.
27. de Coaña Pico. Y, Choudhury A, Kiessling R. Checkpoint blockade for cancer therapy: revitalizing a suppressed immune system. Trends Mol Med 2015; 21: 482-491.
28. Emens L a, Middleton G. The interplay of immunotherapy and chemotherapy: Harnessing potential synergies. Cancer Immunol Res 2015; 3: 436-443.
29. Butterfield LH. Cancer vaccines. Br Med J 2015; 350: h988.
30. Devaud C, John LB, Westwood JA, et al. Immune modulation of the tumor microenvironment for enhancing cancer immunotherapy. Oncoimmunology 2013; 2: e25961.
31. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363: 711-723.
32. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012; 366: 2443-2454.
33. Chmielewski M, Hombach A a., Abken H. Of CARs and TRUCKs: Chimeric antigen receptor (CAR) T cells engineered with an inducible cytokine to modulate the tumor stroma. Immunol Rev 2014; 257: 83-90.
34. Mkrtichyan M, Najjar YG, Raulfs EC, et al. Anti-PD-1 synergizes with cyclophosphamide to induce potent anti-Tumor vaccine effects through novel mechanisms. Eur J Immunol 2011; 41: 2977-2986.
35. Moschella F, Proietti E, Capone I, et al. Combination strategies for enhancing the efficacy of immunotherapy in cancer patients. Ann NY Acad Sci 2010; 1194: 169-178.
36. Pastore A, Jurinovic V, Kridel R, et al. Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry. Lancet Oncol 2015; 16: 1111-1122.
37. Tesniere A, Schlemmer F, Boige V, et al. Immunogenic death of colon cancer cells treated with oxaliplatin. Oncogene 2010; 29: 482-491.
38. Vacchelli E, Martins I, Eggermont A, et al. Chemotherapy with immunogenic cell death inducers. Oncoimmunology 2012; 1: 1557-1576.
39. Suzuki E, Kapoor V, Jassar AS, et al. Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity. Clin Cancer Res 2005; 11: 6713-6721.
40. Trojandt S, Knies D, Pektor S, et al. The chemotherapeutic agent topotecan differentially modulates the phenotype and function of dendritic cells. Cancer Immunol Immunother 2013; 62: 1315-1326.
41. Li JY, Duan XF, Wang LP, et al. Selective depletion of regulatory T cell subsets by docetaxel treatment in patients with nonsmall cell lung cancer. J Immunol Res 2014; 2014: 286170.
42. Tanaka H, Matsushima H, Nishibu A, et al. Dual therapeutic efficacy of vinblastine as a unique chemotherapeutic agent capable of inducing dendritic cell maturation. Cancer Res 2009; 69: 6987-6994.
43. Mattarollo SR, Loi S, Duret H, et al. Pivotal Role of innate and adaptive immunity in anthracycline chemotherapy of established tumors. Cancer Res 2011; 71: 4809-4820.
44. Cao C, Han Y, Ren Y, et al. Mitoxantrone-mediated apoptotic B16-F1 cells induce specific anti-Tumor immune response. Cell Mol Immunol 2009; 6: 469-475.
45. Van den Eynde B, Lethé B, Van Pel A, et al. The gene coding for a major tumor rejection antigen of tumor P815 is identical to the normal gene of syngeneic DBA/2 mice. J Exp Med 1991; 173: 1373-1384.
46. Amar-Costesec A, Godelaine D, Van den Eynde B, et al. Identification and characterization of the tumor-specific P1A gene product. Biol cell 1994; 81: 195-203.
47. Chen YT, Scanlan MJ, Sahin U, et al. A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc Natl Acad Sci USA 1997; 94: 1914-1918.
48. Wölfel T, Hauer M, Schneider J, et al. A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science 1995; 269: 1281-1284.
49. Peiper M, Goedegebuure PS, Linehan DC, et al. The HER2/neu-derived peptide p654-662 is a tumor-Associated antigen in human pancreatic cancer recognized by cytotoxic T lymphocytes. Eur J Immunol 1997; 27: 1115-1123.
50. Keskin DB, Reinhold B, Lee SY, et al. Direct identification of an HPV-16 tumor antigen from cervical cancer biopsy specimens. Front Immunol 2011; 2: 75.
51. Bloom MB, Perry-Lalley D, Robbins PF, et al. Identification of tyrosinase-related protein 2 as a tumor rejection antigen for the B16 melanoma. J Exp Med 1997; 185: 453-459.
52. Teillaud JL. Microenvironnements tumoraux: conflictuels et complémentaires. Med Sci (Paris) 2014; 30: 343-466.
53. Teillaud JL. Quand les anticorps rencontrent l'immunité antitumorale: fin de partie pour la cellule cancéreuse ? Med Sci (Paris) 2015; 31: 707-708.
54. Teillaud JL, Watier H, Beck A. Anticorps monoclonaux en thérapeutique. Med Sci (Paris) 2009; 25: 995-1196.